Company / Free Cash Flow per Share
Sarepta Therapeutics Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$3.17
FY2025
5-year range
-$6.56 / $0.29
FY2021-FY2025
Trend
+13.2%
vs FY2024
Sector context
#153 of 192
Health Care
What the data says
Sarepta Therapeutics's free cash flow per share of $-3.17 is lower than 80% of companies in the Health Care sector (FY2025). Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-6.94 in FY2018 to $0.29 in FY2022.
Based on SEC 10-K filings.
-3.17 in FY2025.
Improved from $-6.56 to $-3.17 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 192This company -$3.17 Sector average -$19.84
▼
+84.0% above sector average
Key checks
Key Insights
- In FY2025, free cash flow per share increased 13.2% year-over-year.
- Ranks #153 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2022.
- Lowest free cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.17 | +13.2% |
| FY2024 | -$3.66 | +44.3% |
| FY2023 | -$6.56 | -2362.9% |
| FY2022 | $0.29 | +104.8% |
| FY2021 | -$6.07 | -1.4% |
| FY2020 | -$5.98 | -74.3% |
| FY2019 | -$3.43 | +50.5% |
| FY2018 | -$6.94 | -55.8% |
| FY2017 | -$4.46 | +19.0% |
| FY2016 | -$5.50 | -52.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026